Compare Natera Inc. Common Stock (NTRA) vs PNC Financial Services Group Inc. (The) Common Stock (PNC) Price & Performance

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.

PNC trades at $219.48, down 0.8% on the day, with a bearish technical signal but strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue grew to $23.08B in 2025, with net income of $6.94B and a robust net income margin of 31.06%. Analyst consensus is a Buy with a $276.13 price target, indicating significant upside potential from current levels.

The outlook for PNC is positive given its earnings momentum and attractive valuation (P/E of 12.09), though risks include regulatory scrutiny and net cash outflows from investing activities. The stock offers a dividend yield supported by recent increases, positioning it as a value opportunity in the financial sector amid current bearish technical indicators.